98%
921
2 minutes
20
Background And Aims: Bowel preparation is considered as major obstacle before colonoscopy, and it is often reported as the most feared part of the procedure. The aim of this study is to determine the difference in efficacy between a split dose of PEG and the previous day regimen in cleaning the colon, using Boston bowel preparation scale. In addition, also to evaluate patient satisfaction regarding the modality of preparation.
Methods: The study included 200 hospitalized patients undergoing colonoscopy at Beirut hospitals between 2021 and 2023. One of the two regimens will be prescribed randomly to the patients before colonoscopy: 98 (49%) in Group A (patients treated with PEG preparation as a split dose for 2 days), and 102 (51%) in Group B (patients taking PEG preparation as a whole dose). Data was analyzed using SPSS version 25.
Results: Patients were distributed between 105 (52.5%) males and 95 (47.5%) females. The top two indications for colonoscopy were bleeding (34%), change in bowel habits (constipation/diarrhea) (32%). Patients experienced adverse events noting cramps (48.5%), stomach ache (32%), headache (31%), vomiting (53%), nausea (53%), sleep disturbance (27%), bloating (26.5%), and malaise (26%). A statistically significant difference ( = 0.040) was detected in sleep disturbance: 20.4% of patients in group A and 33.3% of patients in group B. The average satisfaction score was 3.02 ± 1.03 over 4 (Group A) and 3.04 ± 0.99 over 4 (Group B) ( = 0.896). The average BBPS was 8.07 ± 1.14 (Group A) and 8.28 ± 1.0 (Group B) ( = 0.162).
Conclusion: The two administrations were almost similar in term of satisfaction and BBPS. As multiple factors like age, sexe, comorbidities may contribute in altering how much a given drug is safe and efficace, more research is needed to choose the best 3regimen for each patient.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11035750 | PMC |
http://dx.doi.org/10.1002/hsr2.2047 | DOI Listing |
United European Gastroenterol J
September 2025
Sheba Medical Center Tel Hashomer, Faculty of Medical and Health Sciences, Gastroenterology Institute, Tel-Aviv University, Tel Aviv, Israel.
Background: Mucosal healing (MH) is a key treatment goal in Crohn's disease (CD). However, evidence on pan-enteric MH (PE-MH) in CD patients treated with vedolizumab remains limited. We aimed to assess vedolizumab efficacy in achieving PE-MH using PillCam Crohn's capsule.
View Article and Find Full Text PDFDis Colon Rectum
September 2025
Immune Health Research Program, Hunter Medical Research Institute, New Lambton Heights, NSW, Australia.
Endoscopy
September 2025
Dept. of Gastroenterology and Hepatology and Hepatology, Erasmus MC University Medical Center, Rotterdam, Netherlands.
Background: Bowel preparation is essential for colonoscopy but may deter patients. Although low-volume laxatives are better tolerated, their impact on patient-reported outcomes remains unclear. We compared low- and intermediate volume bowel preparation and assessed the impact on tolerability, health-related quality of life (HRQoL) and work.
View Article and Find Full Text PDFEndoscopy
September 2025
Centre for Biomaterials and Tissue Engineering, Universitat Politècnica de València, Valencia, Spain.
Objectives: We aimed to perform a multifactorial carbon footprint assessment and sensitivity analysis of the colonoscopy procedure.
Design: One-week single-center prospective study with all outpatients' diagnostic colonoscopies was realized (n=66). A cradle-to-grave life cycle assessment (LCA) methodology evaluated all essential supplies (accessories from 1 to 15), endoscopic procedure (energy consumption, CO2 insufflation, bowel preparation, and sedation), staff and patients transport and waste management.
World J Methodol
December 2025
Department of Internal Medicine, University of Tabuk, Saudi Arabia, Tabuk 51941, Saudi Arabia.
Background: Irritable bowel syndrome (IBS) is a prevalent functional gastrointestinal (FGITD) disorder, the diagnosis is based on Rome Criteria and other subjective tools. Because IBS overlaps with other FGITD and organic diseases, and the subjective tools do not apply to patients with cognitive decline, objective diagnostic tools are important in this category of patients.
Aim: To discuss the role of imaging in IBS diagnosis.